The Antibiotic Opportunity? Spero’s Ankit Mahadevia on The Long Run Podcast

Today’s guest on The Long Run podcast is Ankit Mahadevia. Mahadevia is the CEO of Cambridge, Mass.-based Spero Therapeutics. It’s an antibiotic developer. Specifically, it’s focused on new strategies for fighting gram-negative bacterial infections that are increasingly resistant to our existing set of antibiotics. Despite persistent warnings from global health authorities about the rise of multi-drug resistant bugs, and the...
Read More

Finding the ‘Middle Market’ of Biotech VC: Chris Garabedian on The Long Run Podcast

Today’s guest on The Long Run podcast is Chris Garabedian. Garabedian is best known for his controversial stint as CEO of Cambridge, Mass.-based Sarepta Therapeutics, the developer of treatments for Duchenne Muscular Dystrophy. Whatever you may think of his tenure there — and the FDA’s decision to approve eteplirsen on a slim reed of clinical trial evidence – there is...
Read More

Impact in More Ways Than One: Tony Coles on The Long Run Podcast

I’m happy to introduce the latest guest on The Long Run podcast — Tony Coles. He is the co-founder and CEO of Yumanity Therapeutics, a Cambridge, Mass.-based company doing drug discovery work against neurodegenerative diseases. That means Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (Lou Gehrig’s disease). This is a fascinating time to be focused on neurodegenerative diseases. The...
Read More
1 2 3 24